The following article was written by Donna J. Harrison the Executive Director of the American Association of Pro-Life Obstetricians and Gynecologists AAPOG.
About a month ago, the Journal of Obstetrics and Gynecology published a case report on another death from medical abortion. Of course this death, as most of the others, was ignored by the international press.
“Currently most of the adverse events for medical abortion come from Danco, the company who makes mifepristone. It is extremely unlikely that FDA (US Food and Drug Administration) is getting the entire story from the fox who is watching the hen-house.”
One blogger, however has published an excellent summary of the case as well as a historical review of other cases of death from C. sordellii. His excellent summary is found here Click here for video on Abortion Pill Risks (medical abortion)
His conclusions (shown below) are worth serious consideration:
Patients should understand that safe does not mean risk free. Patients should also be informed of all potential risk before they consent to a specific medical abortion procedure and should be vigilant for symptoms after the procedure. Providers must be aware of the potential for complication and death.
Fatal infection following medical abortion has important implications both for the care of individual patients and for the international healthcare community.
Disturbing aspects of many of these medical abortion cases involved women who were young and healthy and all died remarkably rapidly after presentation of infection. (5) (30) (31) (32) (33) (34)
The global deaths in women’s reproductive healthcare are likely to be a minimum number, and the frequency of fatal infection from lethal pathogens in pregnancy remains virtually unknown. (9) (27)
The vital component to drug post-marketing surveillance in the United States and other countries is the voluntary compliance and active engagement by the health care community in recognizing and reporting adverse events.” (28)"
As obgyns and other women’s health care providers, we will be the ones taking care of these patients in the ER, or hearing about these patients from colleagues. It is vitally important that we utilize the MEDWATCH Reporting system set up by the FDA to report adverse events subsequent to medical abortion.
Serious adverse events include not only deaths, but hemorrhages, hospitalizations, serious infections and any event which if left untreated could result in significant morbidity or mortality.
The FDA keeps a record of every adverse event reported. Currently most of the adverse events for medical abortion come from Danco, the company who makes mifepristone. It is extremely unlikely that FDA is getting the entire story from the fox who is watching the hen-house. Please encourage your colleagues to report adverse events associated with medical abortions directly to the FDA.